Chemotherapy-induced peripheral neuropathy in pediatric cancer patients.
Chemotherapy forms the backbone of treatment for many types of pediatric cancers, but a main side effect of treatment is chemotherapy-induced peripheral neuropathy (CIPN). Damage to the peripheral nervous system by chemotherapeutic agents can occur at the axon, cell body, or myelin level, and the mechanism of damage differs based on the specific chemotherapeutic agent used. This review provides background on the current knowledge of pathophysiology, assessment, and intervention for CIPN, focusing specifically on issues relevant in pediatric cancers patients. Although specific, standardized measures of CIPN are available for adults, such measures are limited for use in the pediatric populations. Likewise, clinical trials for prevention and treatment of this neuropathy and related symptoms are rare in pediatrics, but some information can be gained from the basic and adult literature.
Hematology and Oncology Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN, USA. lsgilchrist@stkate.edu
Laura
L
Gilchrist
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control / Q000628:therapy
D000970:Antineoplastic Agents